Developing global, high-value products for patients with significant unmet medical needs in niche indications
Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.
A potential treatment for patients with IgA nephropathy at risk of developing ESRD.
IPO Calliditas Therapeutics
On August 16, 2018, at 07:00am CEST, Calliditas Therapeutics will publish its interim report for the second quarter of 2018.
Calliditas Therapeutics AB
SE-111 24 Stockholm
Company number: 556659-9766
© Calliditas Therapeutics AB 2018